Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of Views

<< 2011 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2013 >>

27 July 2012: Britain Unleashed: our world-class universities can lead us to prosperity

Britain’s universities are international powerhouses of research, innovation and education – used properly they can and will sustain immediate and long term economic prosperity, says Stephen Caddick.
More...

19 July 2012: Open access plan is no academic spring

The government argues that "gold" open access will give us a competitive economic advantage. It will not. The approach as it stands will increase the cost of research but, without reciprocal international agreement, will likely offer a competitive advantage to those who do not invest in UK research.
More...

<< 2011 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2013 >>